^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IK-175

    i
    Other names: IK-175, KYN-175
    Company:
    Ikena Oncology
    Drug class:
    AHR antagonist
    Related drugs:
    2ms
    Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer (clinicaltrials.gov)
    P1, N=0, Withdrawn, Ikena Oncology | Phase classification: P1b --> P1 | N=54 --> 0 | Trial completion date: Jul 2025 --> Apr 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Apr 2023
    Phase classification • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • IK-175
    2ms
    A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=78, Completed, Ikena Oncology | Recruiting --> Completed | Trial completion date: Sep 2022 --> Jul 2023 | Trial primary completion date: Sep 2022 --> Jul 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    Opdivo (nivolumab) • IK-175
    almost2years
    Discovery and characterization of a novel aryl hydrocarbon receptor inhibitor, IK-175, and its inhibitory activity on tumor immune suppression. (PubMed, Mol Cancer Ther)
    These studies provide rationale for targeting AHR in cancer patients. IK-175 is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IL17A (Interleukin 17A) • IL22 (Interleukin 22) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)
    |
    IK-175
    almost2years
    Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer (clinicaltrials.gov)
    P1b, N=54, Not yet recruiting, Ikena Oncology
    New P1 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • IK-175
    over2years
    Analytical validation of a novel immunohistochemistry assay to determine nuclear AHR expression in human bladder cancer (SITC 2021)
    IK-175 is being evaluated in an ongoing phase 1 clinical study as a single agent and in combination with nivolumab for bladder cancer patients (NCT04200963). Conclusions A novel and robust nuclear AHR IHC assay for bladder cancer was developed and analytically validated in a CLIA certified lab and showed ≥95% accuracy, specificity, sensitivity, and precision, enabling its implementation in an IK-175 Ph1b clinical study (NCT04200963) for prospective patient enrichment. Trial Registration NCT04200963
    PD(L)-1 Biomarker • IO biomarker
    |
    AHR (Aryl hydrocarbon receptor)
    |
    AHR expression
    |
    Opdivo (nivolumab) • IK-175